Merck’s once-monthly oral HIV prevention pill, MK-8527, advances to Phase III and may offer an accessible PrEP option in the future.

GEMORNA could turn out to be a sea change for biopharma firms pursuing mRNA-based medicines beyond traditional infectious disease vaccines.

Findings suggest that because the brain maps are preserved, it may, theoretically, be possible to restore movement to a ...

The foundation is launching with an initial slate of grants to local scientific centers of excellence in Seattle.

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

Stem cells cryopreserved on the International Space Station for six months have successfully produced healthy mouse offspring ...

The open-source pipeline designs proteins with improved success rates for therapeutic targets, including gene editing proteins and allergens.

Blueprint for ovarian reserve cell development identifies critical development milestones, risk factors for hormone-related disorders.

A new delivery platform allows protein therapeutics to be delivered in higher concentrations and injected with a standard ...

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to $1.

Antibodies from a person who had previously been infected with mpox provides full protection from severe illness and death in mice.

Researchers have created a blueprint of how one of the world's most dangerous toxins, botulinum toxin, is structured, stabilized, delivered and released.